Semaglutide Patent Expiration: Implications for Patients, Pharmaceutical Companies, and Novo Nordisk

Semaglutide Generic Entry to Reshape India's Diabetes and Obesity Market

March 20, 2024: The patent for Novo Nordisk's semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, has expired in India, allowing multiple Indian pharmaceutical companies to launch generic versions of the blockbuster diabetes and weight-loss drug.

Key Players: Indian pharma majors Sun Pharma, Dr Reddy’s, Zydus, Lupin, Natco, and Mankind will enter the market on March 21, leading to a potential price drop of 50-70% for the drug. This translates to monthly costs of Rs 3,000-5,000 per month.

Impact on Patients: The entry of generics is expected to increase access to semaglutide for millions of diabetic and obese patients in India's largely out-of-pocket healthcare system. However, experts caution against misuse and side-effects, emphasizing the need for strict nutritional adherence and expert oversight.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

Medical Expert Insights: Dr Shashank Joshi, an endocrinologist, calls semaglutide a "game-changing, disease-modifying drug" that works on glucose, weight, and metabolic complications simultaneously. Dr Bhupen Desai, a cardiologist, points to the SUSTAIN-6 trial, which found semaglutide reduces heart attack risk by 26% and stroke risk by 39%.

Clinical Trial Data: Semaglutide is supported by one of the strongest evidence bases in metabolic medicine, with over 70 clinical studies involving more than 20,000 patients. The drug has demonstrated substantial HbA1c reductions and 10-15% or more weight loss, enabling diabetes remission in selected early-stage patients.

Side-Effects and Misuse: Experts warn against unsupervised use and side-effects, including nausea, pancreatitis, gallbladder problems, kidney issues, and severe allergic reactions. The growing culture of unsupervised use, fueled by social-media testimonials, could trigger preventable harm.